Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
Status:
Active, not recruiting
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, tolerability, feasibility and
preliminary efficacy of the administration of PBF-509 (Adenosine A2a receptor antagonist) as
single agent or in combination with PDR001 (programmed cell death 1 receptor antibody (PD-1
Ab)) to NSCLC patients.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Palobiofarma SL
Collaborators:
H. Lee Moffitt Cancer Center and Research Institute Novartis